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II  Summary 
Photoreceptors are highly specialized cells required for phototransduction within the 
retina and thus crucial for visual perception. Inherited retinal diseases are mainly 
caused by mutations in photoreceptor-specific genes, the majority of which is 
regulated by the key transcription factor cone rod homeobox (CRX). Using genome-
wide chromatin immunoprecipitation data (CRX ChIP-seq), we have identified a novel 
sterile alpha motif (SAM) domain containing protein, SAMD7, as a CRX target. 
SAMD7 is expressed in the mouse retina and pineal gland and localizes to the 
cytoplasm and nucleus of photoreceptor cells. SAMD7 expression is regulated by 
CRX, which binds to two specific regions in the promoter and first intron (enhancer) 
of the SAMD7 gene. Consequently, CRX knock-down leads to a significant decrease 
of SAMD7 enhancer activity and protein levels in the retina. Functionally, SAMD7 
acts as a transcriptional repressor of CRX-mediated photoreceptor gene expression, 
indicating that mutations in or dysregulation of SAMD7 could lead to disturbed 
photoreceptor homeostasis and ultimately retinal degeneration.  
Microglial cells are the resident macrophages of the central nervous system (CNS), 
including the retina, and play pivotal roles in innate immune responses and regulation 
of homeostasis in the healthy and degenerating CNS. Reactive microgliosis is a 
common hallmark of neurodegenerative diseases and chronic pro-inflammatory 
microglial reactivity contributes to disease progression. We have previously identified 
activated microglia/macrophage whey acidic protein (AMWAP) as a biomarker for 
microglial reactivity and counter-regulator of pro-inflammatory response. AMWAP is 
actively secreted from lipopolysaccharide (LPS)-activated microglia and recombinant 
AMWAP is taken up by microglial cells in a paracrine fashion and effectively reduces 
TLR2- and TLR4-mediated pro-inflammatory gene expression. AMWAP exerts its 
anti-inflammatory function through blockade of NFκB activation, as it inhibits 
proteolysis of the NFκB pathway mediators IRAK-1 and IκBα without preventing IκBα 
phosphorylation and ubiquitination or affecting overall 20S proteasome activity. 
Functionally, AMWAP reduces pro-inflammatory microglial nitric oxide (NO) secretion 
and neurotoxicity on photoreceptor cells in vitro. Further, AMWAP promotes filopodia 
formation of microglia and increases the phagocytic recognition and uptake of 
apoptotic photoreceptor debris, common features of homeostatic regulatory 
microglia. We therefore hypothesize that anti-inflammatory whey acidic proteins 
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(WAPs) could have therapeutic potential in neurodegenerative diseases of the brain 
and retina. 
The translocator protein (18 kDa) (TSPO) is a mitochondrial protein expressed in 
reactive glial cells and a biomarker for gliosis in the brain but has not been 
investigated in a retinal context so far. Various TSPO ligands have been shown to 
reduce neuroinflammation in neurodegenerative mouse models. We could show 
strong upregulation of TSPO transcript and protein levels in reactive microglial cells 
in vitro, microglia of the retinoschisin-deficient retinal degeneration mouse model as 
well as TSPO expression in microglia of the human retina. TSPO mRNA expression 
is high in the developing mouse retina and declines to low levels in the adult tissue. 
The synthetic TSPO ligand XBD173 effectively suppresses pro-inflammatory 
microglial gene expression, migration, proliferation, NO secretion and neurotoxicity 
on photoreceptors in vitro. Further, XBD173 treatment promotes filopodia formation 
and increases the phagocytic recognition and uptake of latex beads and apoptotic 
photoreceptor debris by murine and human microglial cells in vitro. Finally, XBD173 
effectively reduces the number of amoeboid alerted microglia in organotypic murine 
retinal explant cultures stimulated with LPS. In conclusion, we have identified TSPO 
as a novel marker for microglial reactivity in the retina and a potential therapeutic 
target to reduce chronic neuroinflammation during retinal degeneration. 
In summary, our studies on the novel photoreceptor gene regulator SAMD7 and the 
microglial reactivity markers AMWAP and TSPO provide insights into potential 
disease mechanisms of retinal degeneration and suggest future strategies of 
identifying and therapeutically modulating pro-inflammatory microglial reactivity in 
degenerative diseases of the CNS and retina. 
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III  Zusammenfassung 
Photorezeptorzellen sind hoch spezialisierte Zellen innerhalb der Netzhaut, welche 
die Phototransduktion vermitteln und daher essentiell für die Aufnahme und 
Verarbeitung visueller Sinnesreize sind. Erbliche Netzhautdystrophien werden 
vornehmlich durch Mutationen in Photorezeptor-spezifischen Genen verursacht, von 
welchen die Mehrzahl durch den Schlüsseltranskriptionsfaktor cone rod homeobox 
(CRX) reguliert wird. Mit Hilfe eines genomweiten Chromatin Immunpräzipitations-
Datensatzes (CRX ChIP-seq), konnten wir ein neuartiges, sterile alpha motif (SAM) 
Domänen beinhaltendes Protein, SAMD7, als CRX Zielgen identifizieren. SAMD7 
wird in der Mausnetzhaut und Zirbeldrüse exprimiert und lokalisiert im Zytoplasma 
und Nukleus von Photorezeptorzellen. Die SAMD7 Expression wird durch CRX 
reguliert, welches an zwei spezifischen Regionen im Promotor und ersten Intron 
(Enhancer) im SAMD7 Gen bindet. Somit führt CRX knock-down zu einer 
signifikanten Abnahme der regulatorischen Aktivität des SAMD7 Enhancers und der 
SAMD7 Proteinlevel in der Netzhaut. Funktionell agiert SAMD7 als 
Transkriptionsrepressor der CRX-vermittelten Photorezeptor-Genexpression, was 
darauf hindeutet, dass Mutationen in oder Dysregulation von SAMD7 zu gestörter 
Photorezeptor-Homöostase und letztlich zu Netzhautdegeneration führen könnten.  
Mikrogliazellen sind die gewebsansässigen Makrophagen des zentralen Nerven-
systems (ZNS), inklusive der Netzhaut, und spielen eine wichtige Rolle in der 
Immunantwort und Regulation der Homöostase im gesunden sowie degenerierenden 
ZNS. Reaktive Mikrogliose ist ein typisches Merkmal neurodegenerativer 
Erkrankungen und chronische proinflammatorische Mikrogliaaktivierung beschleunigt 
den Krankheitsverlauf. Wir konnten in Vorarbeiten das activated microglia/ 
macrophage whey acidic protein (AMWAP) als Biomarker für reaktive Mikroglia und 
Gegenspieler der proinflammatorischen Mikrogliaantwort identifizieren. AMWAP wird 
aktiv von Lipopolysaccharid (LPS)-aktivierten Mikroglia sezerniert und rekombinantes 
AMWAP wird in parakriner Weise von Mikroglia aufgenommen in welchen es effektiv 
die TLR2- und TLR4-vermittelte proinflammatorische Genexpression reduziert. 
AMWAP erzielt diese antiinflammatorische Wirkung durch Blockade der NFκB 
Aktivierung, indem es die Proteolyse der NFκB Signalwegsmediatoren IRAK-1 und 
IκBα verhindert ohne die IκBα Phosphorylierung, Ubiquitinierung oder die allgemeine 
20S Proteasomaktivität zu beeinflussen. Funktionell reduziert AMWAP die proinflam-
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matorische mikrogliale Stickstoffoxidsekretion und Neurotoxizität gegenüber Photo-
rezeptorzellen in vitro. Des Weiteren induziert AMWAP die Bildung mikroglialer 
Filopodien und erhöht die phagozytische Aufnahmefähigkeit von apoptotischem 
Photorezeptordebris, typische Charakteristika homöostatischer und regulatorischer 
Mikroglia. Wir schließen aus diesen Ergebnissen, dass antiinflammatorische whey 
acidic proteins (WAPs) therapeutisches Potential in neurodegenerativen Erkran-
kungen des Gehirns und der Netzhaut haben könnten. 
Das Translokatorprotein (18 kDa) (TSPO) ist ein mitochondriales Protein, welches in 
reaktiven Gliazellen exprimiert ist, als Gliosemarker im Gehirn fungiert und bisher 
noch nicht im retinalen Kontext untersucht wurde. Verschiedene TSPO Liganden 
reduzieren Neuroinflammation in neurodegenerativen Mausmodellen. Wir konnten 
eine starke Hochregulation der TSPO Transkript- und Proteinlevels in reaktiven 
Mikrogliazellen in vitro, Mikroglia des Retinoschisin-defizienten Mausmodells sowie 
TSPO Expression in Mikroglia der humanen Netzhaut nachweisen. TSPO ist auf 
mRNA Ebene stark in der sich entwickelnden Mausnetzhaut exprimiert und sinkt auf 
ein niedrigeres Niveau im adulten Gewebe. Der synthetische TSPO Ligand XBD173 
verringert effektiv die proinflammatorische mikrogliale Genexpression, Migration, 
Proliferation, Stickstoffoxid-Sekretion und Neurotoxizität gegenüber Photorezeptor-
zellen in vitro. Außerdem induziert XBD173 die Bildung mikroglialer Filopodien und 
erhöht die phagozytische Aufnahmefähigkeit von Latexkügelchen und apoptotischem 
Photorezeptordebris durch murine und humane Mikrogliazellen in vitro. Weiterhin 
reduziert XBD173-Behandlung effektiv die Zahl amöboider, alarmierter Mikroglia-
zellen in LPS-stimulierten organtypischen Netzhautexplantatkulturen. Schluss-
folgernd konnten wir TSPO als neuartigen Marker der Mikrogliaaktivierung in der 
Netzhaut und potentielle therapeutische Zielstruktur zur Reduktion chronischer 
Neuroinflammation während Netzhautdegeneration identifizieren. 
Zusammenfassend ermöglichen unsere Untersuchungen zum neuartigen 
Photorezeptor-Genregulator SAMD7 und den mikroglialen Reaktivitätsmarkern 
AMWAP und TSPO einen Einblick in mögliche Pathomechanismen retinaler 
Degeneration und offenbaren Möglichkeiten zur Identifizierung und therapeutischen 
Modulation pro-inflammatorischer Mikrogliaaktivität in degenerativen Erkrankungen 
des ZNS und der Netzhaut. 




1.1 Structure and function of the mammalian retina 
Visual perception represents one of our most important senses and enables us to 
experience our environment in a remarkable fashion and detail. The complex 
mechanisms underlying the transformation of light into visual stimuli have fascinated 
humans for centuries. Electromagnetic rays between 400-750 nm wavelengths are 
recognizable to humans as visible light, and the tissue crucial for this process is the 
retina with its different cellular layers. In opposition to the peripheral sensory organs, 
the retina is a direct component of the central nervous system (CNS), as it 
developmentally represents an evagination of the diencephalon. 
 
Figure 1: Gross anatomy of the eyeball and detailed cross-section of the retina and its different cell types. 
(A) The retina lines the posterior segment of the eyeball and lies adjacent on top of the retinal pigment epithelium 
(RPE). (B) Histological cross-section of the retina depicting its different cell layers. GCL, ganglion cell layer; IPL, 
inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; IS, 
photoreceptor inner segment; OS, photoreceptor outer segment; RPE, retinal pigment epithelium. (C) Schematic 
overview of the different cell types within the retinal layers. G, ganglion cell; A, amacrine cell; B, bipolar cell; H, 
horizontal cell; M, Mueller cell; R, rod photoreceptor; C, cone photoreceptor; RPE, retinal pigment epithelium. 
(Eyeball modified from http://www.garetina.com/about-the-eye, retinal cross section modified from 
http://www.oculist.net/downaton502/prof/ebook/duanes/pages/v8/v8c013.html, schematic section adapted from 
Sung and Chuang, 2010). 
Within the eye, the retina lies directly adjacent on top of the retinal pigment 
epithelium (RPE) (Fig. 1 A), which has important housekeeping functions like vitamin 
A metabolism, heat regulation and constant shedding of photoreceptor outer 
segments containing the visual pigment (opsins) through phagocytosis. Further, the 
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RPE functions as outer blood retinal barrier, ensuring that only molecules below a 
certain size translocate from the choroidea into the neuroretina. The choroidea 
serves as a key structure for supporting blood vessels, and the sclera, as the 
outermost layer of the eye, provides stability and is attached to the ocular muscles. In 
spite of being only ~200 µm thick, the retina consists of three distinct cellular layers, 
harboring many different cell classes (Fig. 1 B, C) (Klinke et al., 2003). The innermost 
layer consists of ganglion cells (GCs), whose axons converge to form the optic nerve 
and transmit visual signals to the brain. Adjacent lays the inner nuclear layer (INL), 
consisting of amacrine, bipolar and horizontal cells, preprocessing visual signals and 
increasing contrast. After passing through these layers, light reaches the outer 
nuclear layer (ONL), which harbors the cell bodies of photoreceptors. There are two 
distinct types of photoreceptors: cones and rods. The human retina harbors around 
130 million photoreceptors, of which 95% represent rods (Sung and Chuang, 2010). 
Cones are responsible for high resolution color vision and the perception of objects in 
bright light conditions (photopic vision), whereas rods are responsible for perception 
in dim light conditions and night vision (scotopic vision) (Baylor et al., 1979, Klinke et 
al., 2003). 
Absorption of photons by opsins in the photoreceptor outer segment (OS) leads to 
isomerization of 11-cis retinal to all-trans retinal and triggers the phototransduction 
cascade including hyperpolarization of photoreceptor cell membranes. The signal is 
then transmitted to the neurons of the INL and finally reaches the ganglion cells, 
which possess long axons that unite at the so-called “blind spot”, which is devoid of 
photoreceptors and where the optic nerve exits the eyeball. Roughly 3.5 mm distant 
lies the fovea centralis (in the center of the macula), which is comprised solely of 
cones and represents the area enabling sharp central vision within the retina. In the 
fovea, each cone cell is connected to a single bipolar and ganglion cell, enabling 
particularly focused vision in this area compared to the peripheral retina. Mueller cells 
represent one out of three glial cell moieties in the retina (Mueller glia, astroglia and 
microglia). They serve as support cells for retinal neurons and span throughout all 
retinal layers. In recent years, an additional function of Mueller cells as optic fibers 
facilitating the transmission of light through the retina towards the photoreceptors has 
been described (Reichenbach and Bringmann, 2013).  
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The retina is devoid of pain receptors, therefore neuroretinal diseases remain largely 
pain-free and impairment of visual perception should be monitored and examined 
thoroughly. One of the main causes of impaired vision in inherited retinal 
degenerations is the irreversible loss of photoreceptors due to retinal damage or 
mutations in photoreceptor-specific genes leading to apoptosis (Rattner et al., 1999).  
The murine retina is to a large extent structurally similar to the human retina, there 
are however certain distinctions to be considered. Around 75% of the murine retina 
account for photoreceptors, of which 97% are rods. Mice almost exclusively rely on 
rod-mediated scotopic vision and, in contrast to humans (red, green and blue), are 
only equipped with two types of cones for either short or middle-to-long wavelengths 
of light (Morrow et al., 1998). Most importantly, the murine retina does not harbor a 
macula or fovea. 
 
1.2 Retinal genetics 
1.2.1 Inherited retinal degenerations 
Since the retina is comprised of a complex network of highly specialized cells, it is 
highly susceptible to genetic defects leading to hereditary retinal dystrophies, a major 
cause of legal blindness worldwide. To date, the Retnet database 
(https://sph.uth.edu/retnet/ as of July 28th 2015) lists a total of 278 genes and loci 
linked with retinal degenerations. 64 of these genes are causative for the most 
frequent monogenic group of disorders, retinitis pigmentosa (RP). On the other hand, 
the leading cause of legal blindness in the elderly of industrialized nations today is 
age-related macular degeneration (AMD), a complex genetic disease. In contrast to 
RP, a multitude of genetic risk variants as well as environmental risk factors 
contribute to the development of AMD and ultimately loss of vision (Jager et al., 
2008, Chen et al., 2010).  
Various animal models have been generated over the last decades, mimicking 
hereditary retinal degenerative diseases like retinitis pigmentosa (Rivas and Vecino, 
2009). X-linked juvenile retinoschisis is another retinal dystrophy affecting patients as 
early as in their adolescence. Retinoschisin-deficient (Rs1h-/Y) mice show an early 
splitting (schisis) of the inner retinal layers followed by photoreceptor degeneration 
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(Weber et al., 2002). Although a plethora of different cellular malfunctions can be the 
underlying cause for monogenic or complex inherited retinal degeneration, 
photoreceptor apoptosis represents a common hallmark of all retinal dystrophies 
during disease progression (Portera-Cailliau et al., 1994, Sancho-Pelluz et al., 2008). 
Within the large group of causative genes, defects in retina-specific genes and 
master transcription factors are frequently associated with inherited retinal 
dystrophies (Rattner et al., 1999, Tran and Chen, 2014). Photoreceptors are highly 
specialized cells with a multitude of intracellular components and functions and 
therefore highly prone to various genetic malfunctions, ultimately leading to 
photoreceptor degeneration (Bramall et al., 2010). High transcript levels of a gene in 
photoreceptors and a dysfunction of the corresponding protein are tightly associated 
with retinal degeneration, indicating that knowledge about abundantly expressed 
photoreceptor-specific genes, transcription factors and their regulation may help to 
identify novel retinal disease genes (Blackshaw et al., 2001, Wagner et al., 2013). 
 
1.2.2 Regulation of photoreceptor development 
Photoreceptors have a bridging function between our environment and central 
nervous system as they transform light into visual signals within the retina. The 
development of retinal progenitor cells into differentiated, fully functional photo-
receptors is orchestrated by many regulatory events like expression of transcription 
factors, their target genes and cis-regulatory elements that mediate their interaction 
(Hsiau et al., 2007).  
During early retinal development, expression of the transcription factor OTX2 
(orthodenticle homeobox 2) in retinal progenitor cells directs them towards a 
photoreceptor cell fate (Nishida et al., 2003). 12.5 days into the mouse embryonal 
stage (E12.5) OTX2 induces expression of another photoreceptor-specific key 
transcription factor, CRX (cone rod homeobox), in the developing rods and cones 
(Furukawa et al., 1997). From then on, CRX is highly expressed in developing and 
mature photoreceptors indicating its important role in photoreceptor function and 
homeostasis. Additionally, CRX interacts with a variety of other transcription factors 
to influence photoreceptor development and function (Fig. 2). CRX orchestrates this 
network of transcription factors, which regulates whether a progenitor develops into a 
rod or cone photoreceptor. TRB2 (thyroid hormone receptor β2) and RORB (retinoid-
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related orphan receptor β) are crucial factors towards a cone cell fate (Yanagi et al., 
2002, Srinivas et al., 2006), whereas NRL (neural retina leucine zipper) and NR2E3 
(nuclear receptor subfamily 2, group E, member 3) are important mediators of a rod 
cell fate and predominantly expressed in rods (Mears et al., 2001, Milam et al., 
2002).  
 
Figure 2: The transcriptional network of photoreceptor development. The key transcription factor CRX is 
induced by OTX2, represses OTX2 and regulates its own expression. CRX further activates a variety of 
transcription factors important for either a cone or rod photoreceptor cell fate. Activatory (green) and repressory 
(red) influences are depicted as arrows. (Modified from Hsiau et al., 2007). 
This is in line with the observation that NRL- and NR2E3-mutant mice exhibit a 
significant transformation of rods into cones or cone-like photoreceptors (Mears et 
al., 2001, Corbo and Cepko, 2005). CRX interacts synergistically with NRL in mature 
photoreceptors to regulate the expression of rod-specific genes like rhodopsin (Mitton 
et al., 2000). Among the above described, a multitude of additional transcription 
factors play subordinate roles in photoreceptor development (Hsiau et al., 2007). It is 
however fair to say that the beforementioned factors, majorly orchestrated by CRX, 
play the central part (Hennig et al., 2008). 
Severe retinal diseases like cone-rod dystrophy or Leber’s congenital amaurosis are 
caused by mutations in the human CRX gene (Freund et al., 1997, Freund et al., 
1998, Sohocki et al., 1998), while NRL mutations have been associated with retinitis 
pigmentosa (Bessant et al., 1999). CRX overexpression leads to a disproportionally 
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high number of rods and CRX-mutant mice develop photoreceptors lacking outer 
segments and are therefore devoid of visual function (Furukawa et al., 1999). 
 
1.2.3 Genome-wide identification of CRX target genes 
In a genome-wide approach to identify potential novel photoreceptor-specific genes 
including potential disease genes using CRX chromatin immunoprecipitation coupled 
with massively parallel sequencing (CRX ChIP-seq), we could previously identify 
5,595 CRX-bound regions (CBRs) in the regulatory regions of murine photoreceptor 
genes (Corbo et al., 2010). These CBRs show high phylogenetic conservation, 
indicating their functional importance in photoreceptor gene regulation (Visel et al., 
2007). After mapping those target genes to their human orthologues, a total of 724 
CRX-regulated genes, containing a large number of confirmed retinal disease genes, 
could be identified. Employing this dataset, two novel retinitis pigmentosa genes, 
FAM161A and MAK could already be identified (Langmann et al., 2010, Ozgul et al., 
2011) and a recently generated mouse model showing severe FAM161A-associated 
retinal ciliopathy confirmed its role in photoreceptor degeneration (Karlstetter et al., 
2014b). Moreover, the gene causative for cone dystrophy with supernormal rod 
response (CDSRR), KCNV2, was also identified to be highly CRX-regulated which 
we could previously confirm employing electroporation reporter assays in living 
mouse retinas (Aslanidis et al., 2014).  
Interestingly, among the most prominently CRX-bound genes not only known disease 
genes, but also genes that have not been investigated in a retinal context so far, 
were identified. One prominent example of such a gene was sterile alpha motif 
containing 7 (SAMD7). Out of all identified CRX target genes, SAMD7 shows the 
highest CRX binding affinity towards its two single CBRs in the promoter region and 
the first intron, respectively. CRX ChIP-seq of NRL-/- retinas still revealed SAMD7 to 
be highly CRX-bound, indicating that SAMD7 is expressed in both rods and cones, 
since NRL-deficient mice are largely cone-enriched. Additionally, a recent genome-
wide NRL ChIP-seq study confirmed binding of NRL at the above mentioned SAMD7 
cis-regulatory elements (Hao et al., 2012). Further, another ChIP-on-Chip study has 
shown that the promoter region and first intron of SAMD7 are actively bound by RNA-
polymerase II and are thus active transcription start sites in the adult retina (Tummala 
et al., 2010). These findings on SAMD7 as a novel heavily CRX- and NRL-regulated 
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gene in photoreceptors prompted us to take a closer look into its expression, 
regulation and function in the retina. 
 
1.2.4 Sterile alpha motif containing proteins and SAMD7 
Sterile alpha motif (SAM) domains are ~70 amino acid long protein-protein interaction 
domains present in a variety of proteins of different function (Qiao and Bowie, 2005). 
Their initial identification and role in yeast and drosophila fertility together with their 
proposed α-helical structure coined their nomenclature (Ponting, 1995). Around 
1,000 proteins containing SAM domains are found in eukaryotes and some bacteria. 
However, no common functional theme exists for SAM domains (Kim and Bowie, 
2003). These proteins can self-assemble via their SAM domain to build functional 
complexes as well as bind to many other proteins lacking a SAM domain (Kim and 
Bowie, 2003). SAM domain proteins can therefore fulfil a multitude of functions like 
acting as kinases (Tu et al., 1997), regulatory enzymes (Harada et al., 2008), 
scaffolding proteins (Baron et al., 2006), RNA-binding proteins (Aviv et al., 2003) and 
transcriptional regulators (Slupsky et al., 1998). 
Little is known about the role of SAM domain proteins in a retinal context. The SAM 
domain containing ETS transcription factor Yan acts as a negative regulator of 
photoreceptor development in drosophila (Lai and Rubin, 1992) and recently the first 
SAM domain protein exclusively expressed in mouse photoreceptors and the pineal 
gland, Mr-s alias SAMD11 was identified. SAMD11 is CRX-regulated and functions 
as a repressor of CRX-mediated photoreceptor gene expression (Inoue et al., 2006). 
Interestingly, in situ hybridization experiments describe high SAMD7 transcript levels 
in the developing and adult mouse retina (Blackshaw et al., 2001). The emerging role 
of SAM domain proteins in retinal photoreceptors, together with the identification of 
SAMD7 as a highly CRX-regulated gene via CRX ChIP-seq therefore make SAMD7 
a promising gene with potentially important function in photoreceptor development 
and homeostasis. Indeed, we could recently show that SAMD7 acts as a CRX-
regulated repressor of CRX-mediated photoreceptor gene expression in the retina 
(Hlawatsch et al., 2013). 
 
 




1.3.1 Microglia in the CNS and retina 
Microglial cells are the resident macrophages of the CNS, including the retina, and 
play pivotal roles in innate immune responses and regulation of homeostasis in the 
healthy and degenerating CNS (Hanisch and Kettenmann, 2007, Streit, 2002). 
Initially observed by Rio-Hortega as distinct cells with long cellular processes within 
the brain parenchyma, he hypothesized that microglia are mobile, macrophage-like 
cells playing a role in inflammatory nerve tissue (Rio-Hortega, 1939). This hypothesis 
was later confirmed by showing that microglia are indeed bone marrow-derived 
immune-competent cells of the CNS (Hickey and Kimura, 1988). It is now an 
established concept that microglia play important roles in the maintenance of the 
healthy and degenerating CNS in various neurodegenerative diseases (Hanisch and 
Kettenmann, 2007, Heneka et al., 2014). In contrast to macrophages, which are 
derived from postnatal hematopoietic progenitors, microglia originate from myeloid 
precursor cells in the yolk sac during early embryogenesis and populate their 
respective resident tissues in the CNS before formation of the blood-brain and blood-
retina barrier (Ginhoux et al., 2010, Ginhoux and Jung, 2014). Under healthy 
homeostatic conditions, microglia exhibit a ramified morphology with small somata 
and long cellular protrusions, actively scanning their microenvironment for changes 
or injuries in the neuronal tissue (Raivich, 2005). These protrusions are highly motile 
to ensure complete monitoring of the brain parenchyma every few hours 
(Nimmerjahn et al., 2005). In the healthy retina, microglia reside in the inner and 
outer plexiform layers with their small cell bodies, branching their long protrusions 
into the nuclear layers actively surveying the retinal microenvironment (Hume et al., 
1983, Langmann, 2007, Karlstetter et al., 2015). 
 
1.3.2 Functions of microglia 
Microglia carry out a multitude of physiological functions in the developing and adult 
CNS such as regulating apoptosis of specific subpopulations of developing neurons, 
synaptic pruning, modeling and regulation of synaptic plasticity (Marin-Teva et al., 
2004, Coull et al., 2005, Casano and Peri, 2015, Salter and Beggs, 2014). In contrast 
to other neuroglia, microglial cells keep their distance to one another with each single 
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cell surveying its individual territory. It is therefore likely that microglia signal through 
auto- and paracrine mechanisms. Neuron-microglia crosstalk takes place through 
various ligands, receptors, neurotransmitters and neurotrophins (Biber et al., 2007, 
Pocock and Kettenmann, 2007, Vecino et al., 2015). As an example, two well 
characterized ligands, CD200 (cluster of differentiation 200) and CX3CL1 (CX3C 
chemokine ligand 1, alias fractalkine) find their corresponding receptors expressed 
on microglia (Hoek et al., 2000, Cardona et al., 2006). Signaling between those 
ligands and receptors leads to an immunosuppression of microglia, preventing them 
from becoming reactive as well as maintaining their homeostatic regulatory state. In 
addition, these ligands affect microglial migration and ramification movements, 
contributing to the effective monitoring function of microglia (Cardona et al., 2006). 
Another example is the exposition of glycocalyx components on the surface of 
healthy neurons, which microglia recognize via specific Siglec (sialic acid-binding 
immunoglobulin like lectins) receptors (Linnartz-Gerlach et al., 2014). Upon ligand 
binding, Siglecs signal through an immunoreceptor tyrosine-based inhibition motif 
(ITIM) to keep the microglial cell in a regulatory homeostatic state (Wang and 
Neumann, 2010, Claude et al., 2013). However, in early neuronal damage, loss of 
these glycocalyx components leads to rapid complement-mediated pro-inflammatory 
activation of microglia through an immunoreceptor tyrosine-based activation motif 
(ITAM).  
 
Figure 3: Phenotypic plasticity of microglia in the healthy and diseased CNS. Under homeostatic conditions 
(left), microglia exhibit small somata with long, branched protrusions to actively scan their microenvironment and 
carry out tissue maintenance tasks. During degenerative processes in the CNS, microglia are early sensors of 
perturbed tissue homeostasis and undergo a gradual morphological transition (middle) towards amoeboid pro-
inflammatory reactive phagocytes (right). (microglia drawings modified from Karperien et al. (2013)). 
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Upon recognition of disturbed or insulted tissue integrity, microglia undergo 
morphological changes, retracting their cellular protrusions and adopting an 
amoeboid reactive phenotype (Fig. 3) (Hanisch and Kettenmann, 2007). These 
microglial activation cues include damage-associated molecular patterns (DAMPs) 
released from neurons, which are recognized by microglia and lead to toll-like 
receptor (TLR)-mediated pro-inflammatory microglial reactivity (Gao et al., 2011). 
Upon activation, these amoeboid microglia actively migrate towards the lesion site 
where they proliferate, phagocytose apoptotic cells and secrete pro-inflammatory 
cytokines and chemokines like IL6 (interleukin 6), TNFα (tumor necrosis factor α) or 
CCL2 (chemokine (C-C motif) ligand 2) (Banati et al., 1993). Further, they actively 
secrete reactive oxygen species (ROS) and nitric oxide (NO) (Minghetti and Levi, 
1998, Agostinho et al., 2010). Microglia represent the first line of damage response, 
as microglial reactivity occurs very early in response to tissue damage, often 
preceding physiological reactions of any other cell type, like apoptosis (Gehrmann et 
al., 1995). Only minutes after injury, microglia polarize their processes towards the 
lesion site and initiate the inflammatory response (Nimmerjahn et al., 2005). Once 
the pro-inflammatory stimulus has resolved, microglia will return to their regulatory 
state. However, in the case of prolonged insult or neurodegenerative disease, these 
mechanisms may become dysregulated, leading to chronic neuroinflammation which 
can have neurotoxic and detrimental effects including microglial phagocytosis of still 
viable neurons (Block et al., 2007, Brown and Neher, 2014, Zhao et al., 2015). The 
contribution of this reactive microgliosis is nowadays recognized to play a role in 
various neurodegenerative diseases including Alzheimer’s disease, Parkinson’s 
disease, multiple sclerosis, inherited retinal degenerations and several other retinal 
diseases (Perry et al., 2010, Orr et al., 2002, Raivich and Banati, 2004, Langmann, 
2007, Karlstetter et al., 2015). 
 
1.3.3 Microglia in retinal degeneration 
As the retina is part of the CNS, microglia also exert their physiological and 
immunoregulatory functions in this tissue. Regardless of the underlying genetic 
defect or source of retinal injury, pro-inflammatory microglial reactivity is an early 
hallmark and active contributor in retinal degeneration (Thanos, 1991, Langmann, 
2007, Karlstetter et al., 2015). At early stages of disease progression in various 
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retinal degeneration models, reactive retinal microglia retract their cellular protrusions 
and migrate from the plexiform layers to the areas of tissue damage, e.g. the outer 
nuclear layer (ONL) containing photoreceptors, where they act as pro-inflammatory 
phagocytes as mentioned above (Fig. 4) (Zeiss and Johnson, 2004, Combadiere et 
al., 2007, Cuenca et al., 2014).  
 
Figure 4: Schematic overview of microglial distribution and behavior in retinal health and disease. (A) In 
the healthy retina, microglia reside in the plexiform layers, actively scanning their microenvironment with their long 
protrusions (simplified depiction), phagocytosing insoluble metabolites and cellular debris. (B) Upon sensing 
tissue damage, microglia get alarmed, retract their protrusions and migrate into the sites of lesion, where they 
become full-blown pro-inflammatory phagocytes (C), phagocytosing apoptotic cells, secreting cytokines, 
chemokines and neurotoxic radicals. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; 
OPL, outer plexiform layer; ONL, outer nuclear layer; IS, inner segment; OS, outer segment; RPE, retinal pigment 
epithelium. (Karlstetter et al., 2015). 
In the PDE6B (phosphodiesterase 6b)-deficient rd1 and rd10 mouse models, which 
exhibit strong photoreceptor degeneration, a significant number of reactive microglial 
cells is found in the outer nuclear layer secreting high amounts of the pro-
inflammatory mediators TNFα, CCL2 and CCL5 (Zeng et al., 2005, Yoshida et al., 
2013). Further, a recent study has shown that phagocytosis of living photoreceptors 
by reactive microglia contributes to disease progression in the rd10 mouse model 
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(Zhao et al., 2015). In the murine model of X-linked juvenile retinoschisis (Weber et 
al., 2002), an early transformation of microglia into reactive phagocytes, even before 
retinal neurons undergo apoptosis, is observed (Gehrig et al., 2007, Ebert et al., 
2009). These microglial cells show elevated pro-inflammatory transcript expression 
days before neuronal cell death is observable. We recently described a novel model 
of FAM161A-associated photoreceptor ciliopathy, which also exhibits strong 
microgliosis accompanied by pro-inflammatory microglial gene expression in the ONL 
during disease progression which seems to partially resolve after most 
photoreceptors are lost in late disease stages (Karlstetter et al., 2014b). These 
findings indicate that microglial reactivity is a key event in the onset and progression 
of retinal degeneration.  
There is now ample evidence that inflammation and microglia also play important 
roles in the onset and disease progression of AMD (Newman et al., 2012, Penfold et 
al., 2001). In accordance, in post mortem retinas from human AMD and RP patients, 
the presence of reactive microglia bearing phagocytosed apoptotic photoreceptor 
debris was confirmed in the ONL (Gupta et al., 2003). Since mice harbor no macula 
and no archetypical murine AMD model exists to this date, most AMD models focus 
on mimicking single pathological features of the disease like deposition of drusen, 
RPE damage or choroidal neovascularization leading to photoreceptor degeneration. 
In a model of geographic atrophy, which accumulates drusen-like deposits in the 
RPE, reactive phagocytes including microglia accumulate in the outer retina by a 
CCR2 (C-C chemokine receptor type 2)-dependent recruiting mechanism (Hollyfield 
et al., 2010, Cruz-Guilloty et al., 2013). Another strategy of mimicking photo-oxidative 
damage and retinal degeneration present in AMD is irradiation with focused blue or 
intense white light. Blue light-damaged retinas show a high focal accumulation of 
blood-derived macrophages and reactive retinal microglia, and transcriptomic 
analyses confirm the strong inflammatory response of these cells as early as a few 
hours after light damage (Joly et al., 2009, Ebert et al., 2012). Similar observations 
have been made for microglia in the white light damage model which shows early 
CCL2-mediated chemotaxis of reactive microglia to the outer nuclear layer (Santos et 
al., 2010, Suzuki et al., 2012). In recent years, animal models mimicking the wet form 
of AMD including choroidal neovascularization (CNV), employing local rupture of the 
Bruch’s membrane through laser coagulation have proven to be successful (Lambert 
et al., 2013). In this model, reactive microglia are recruited to the lesion site within 
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four hours and peak numbers of reactive phagocytes are found in the subretinal 
space two days after laser damage, long before CNV can be observed (Eter et al., 
2008, Liu et al., 2013).  
These findings indicate the key role of microglia and inflammatory processes during 
early pathogenesis and disease progression of monogenic inherited retinal 
degenerations as well as complex retinal diseases like AMD. 
 
1.3.4 Microglial (reactivity) markers 
With microglia playing a key role in the onset and progression of neurodegenerative 
diseases of the CNS and retina, there is a high interest in discovering microglia-
specific markers to allow for their identification and discrimination between regulatory 
and reactive microglia. Lacking microglia-specific candidates, for decades classical 
macrophage markers like F4/80, CD68 and CD11b were employed to identify 
microglia in the brain and retina (Hume et al., 1983, Xu et al., 2007). In recent years, 
however, IBA1 (ionized calcium-binding adapter molecule 1) has emerged as the 
most reliable and widely used target structure for immunohistochemical detection of 
microglia in the CNS and retina (Ito et al., 1998, Ohsawa et al., 2000).  
Transgenic mice harboring GFP (green fluorescent protein)-positive macrophages 
and microglia are also widely used to simplify recognition of microglia in the immune-
privileged CNS, which is devoid of macrophages under healthy conditions. The 
CX3CR1-GFP knock-in mouse is a widely used example, where all myeloid cells 
express GFP under control of the cell type-specific CX3CR1 promoter on one of their 
CX3CR1 gene copies (Jung et al., 2000). This model has enabled in vivo and live-
imaging of microglial distribution, dynamics and behavior in the healthy and 
degenerating retina (Eter et al., 2008, Lee et al., 2008, Liang et al., 2009). Another 
microglial reporter animal model is the MacGreen mouse. In comparison to the 
CX3CR1-GFP knock-in mouse, this model has the advantage of not replacing a 
functional locus and therefore homozygous mice with potentially stronger GFP 
expression can be used without altering microglial behavior (Sasmono et al., 2003). 
GFP is expressed under the control of the macrophage-specific c-fms (colony 
stimulating factor 1 receptor) promoter and GFP signals in the healthy and 
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degenerating retina overlap nicely with classical immunohistochemical markers IBA1 
and F4/80 (Fig. 5) (Ebert et al., 2009).  
 
Figure 5: Microglial reactivity in the retinoschisin-deficient (Rs1h
-/Y
) mouse retina. (A) In the healthy 
MacGreen GFP reporter mouse, microglia reside in the plexiform layers, exhibit small somata with long cellular 
protrusions (top) and populate the retina in an evenly distributed fashion as shown in retinal flat mount microscopy 
(bottom). (B) In the dystrophic retina, microglia adopt an amoeboid phenotype, lose their even distribution and 
migrate into the site of retinal damage, in this model an early splitting (schisis) of the inner nuclear layer, where 
they act as pro-inflammatory phagocytes. Scale bar, 50 µm. (Flat mount pictures modified from Ebert et. al, 2009). 
Reactive microglia express and secrete a plethora of molecules including classical 
pro-inflammatory mediators like IL1, IL6 and TNFα (Banati et al., 1993, Perry et al., 
2010). This response is largely triggered by pro-inflammatory cytokines like IFNγ 
(interferon γ), TNFs or pathogen-associated molecular patterns (PAMPs) like 
bacterial lipopolysaccharide (LPS) and leads to a classical activation of microglia 
towards an aggressive M1-like macrophage phenotype (Laskin, 2009). However, 
alternative activation of microglia through IL10 or TGFβ (transforming growth factor 
β) towards an M2-like phenotype is associated with resolution of inflammation, 
reduced pro-inflammatory gene expression and increased expression of neurotrophic 
factors, a phenotype more favorable during neurodegenerative diseases (Duffield, 
2003, Cherry et al., 2014). Knowledge about microglial reactivity markers and their 
function is therefore crucial for understanding their individual role in degenerative 
diseases of the CNS and retina.  
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Employing genome-wide expression profiling of microglia from the Rs1h-/Y mouse 
retina, we could recently identify activated microglia/macrophage whey acidic protein 
(AMWAP, alias WFDC17, Gm11428) as a novel marker for microglial reactivity, 
counter-regulating their inflammatory response and thereby serving as a feedback-
loop mechanism to help attenuate pro-inflammatory microgliosis (Gehrig et al., 2007, 
Karlstetter et al., 2010, Aslanidis et al., 2015). We could also show induction of 
AMWAP gene expression in the FAM161A-deficient retinal ciliopathy mouse model, 
congruent with the course and severity of observed microgliosis (Karlstetter et al., 
2014b). In addition, in a recent study we also observed elevated AMWAP transcript 
levels in the retina of the acid sphingomyelinase (aSMase)-deficient mouse model of 
impaired retinal function and reactive microgliosis (Dannhausen et al., 2015). 
Interestingly, transcriptomic profiling using microarray analysis of isolated microglia 
previously also reported a strong upregulation of the back then uncharacterized 
AMWAP transcript (Gm11428) in reactive microglia in a mouse model of severe 
neuronal impairment (Huyghe et al., 2006). 
Further, we and others could show that reactive retinal microglia from Rs1h-/Y and 
aSMase-deficient mice as well as in vitro exhibit strong upregulation of the 
mitochondrial translocator protein (18 kDa) (TSPO) (Karlstetter et al., 2014a, 
Dannhausen et al., 2015, Wang et al., 2014b). These are the first reports of TSPO as 
a microglia reactivity marker and potential therapeutic target in the retina, while 
TSPO has already been implicated to play a role in neuroinflammation of the brain 
and CNS (Girard et al., 2012, Chen and Guilarte, 2008). 
These novel microgliosis markers now serve as assessment tools to evaluate 
microglial reactivity in the retina and are subject of further investigation to elucidate 
their function and employ them as potential mediators of anti-inflammatory 
immunotherapy. 
 
1.3.5 Microglia as a therapeutic target 
Given the important and often detrimental role of chronic pro-inflammatory microglial 
reactivity in degenerative diseases of the CNS and retina, there is a growing interest 
in modulating microglia towards a regulatory, homeostatic phenotype in a therapeutic 
fashion (Schuetz and Thanos, 2004, Karlstetter et al., 2015). Various therapeutic 
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strategies have been investigated so far, including the use of natural compounds, 
endogenous microglial factors as well as synthetic immunoregulatory pharma-
ceuticals.  
 
1.3.5.1 Natural compounds 
Curcumin, a major constituent of turmeric, has been used in Ayurvedic medicine for 
centuries and has broad anti-inflammatory properties (Ammon and Wahl, 1991). 
Curcumin treatment effectively reduces microglial NO secretion, pro-inflammatory 
cytokine expression and migration in vitro (Karlstetter et al., 2011). It further 
attenuates microglial reactivity via blockade of NFκB signaling and is neuroprotective 
in mouse models of intracerebral hemorrhage and traumatic brain injury (Yang et al., 
2014, Zhu et al., 2014a). It was also shown to be protective in various retinal 
degeneration models, inhibiting microglial neurotoxicity and attenuating 
photoreceptor degeneration (Mirza et al., 2013, Gupta et al., 2011, Vasireddy et al., 
2011).  
Luteolin, another natural compound, is a flavonoid abundant in parsley, green pepper 
and celery. Luteolin acts anti-inflammatory through inhibition of pro-inflammatory 
NFκB and AP-1 signaling as well as acting as a radical scavenger (Jang et al., 2008, 
Chen et al., 2007). We could previously show that Luteolin triggers global changes in 
the microglial transcriptome inducing an anti-inflammatory, anti-oxidative and 
neuroprotective phenotype in vitro (Dirscherl et al., 2010). Luteolin further blocks pro-
inflammatory NFκB activation and microglial neurotoxicity in vitro (Zhu et al., 2014b). 
Finally, Luteolin reduces the neurotoxicity of microglia cells on primary hippocampal 
neurons and enhances spatial working memory in aged mice by reducing microglia-
mediated inflammation in the hippocampus (Zhu et al., 2011, Jang et al., 2010).  
Docosahexaenoic acid (DHA) is a polyunsaturated fatty acid enriched in fish oil and 
is highly abundant in the retina as a precursor of neuroprotectin D1 (NPD1), which 
promotes the survival of RPE and photoreceptor cells (Bazan et al., 2010). DHA 
levels were shown to be decreased in various retinal degenerations and DHA is 
therefore regarded as a potential compound for beneficial dietary supplementation 
(Anderson et al., 2002, Schaefer et al., 1995). DHA reduces microglial reactivity 
through inhibition of NFκB signaling and confers neuroprotection in animal models of 
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spinal cord compression and experimental stroke (Wang et al., 2015, Lim et al., 
2013, Eady et al., 2014). In the eye, DHA protects from microglia-mediated retinal 
degeneration in mouse models of X-linked juvenile retinoschisis and neuronal ceroid 
lipofuscinosis (NCL) (Ebert et al., 2009, Mirza et al., 2013).  
 
1.3.5.2 Whey acidic proteins (WAPs) and AMWAP 
Whey acidic proteins (WAPs) are a group of secreted proteins carrying one or more 
WAP four-disulfide core (WFDC) domains, which comprise eight cysteines forming 
four disulfide bonds in a specific manner (Simpson and Nicholas, 2002). They are 
highly enriched at mucosal surfaces like the lung, oral cavity or colon and also 
expressed by neutrophils and macrophages. They fulfil a role as “alarmins”, since 
they are upregulated and actively secreted during tissue damage and inflammation 
(Bingle and Vyakarnam, 2008). They have a broad range of functions, including anti-
microbial, anti-protease and anti-inflammatory potential in the respective tissues 
(Moreau et al., 2008). The best characterized WAPs are secretory leukocyte 
protease inhibitor (SLPI) and elafin (Scott et al., 2011). Both these WAPs serve as 
markers in inflammatory diseases of the lung and colon and have been shown to be 
beneficial for the resolution of inflammation (Tsoumakidou et al., 2010, Eriksson et 
al., 2008, Small et al., 2015, Marino et al., 2011, Reardon et al., 2011). Functionally, 
they can inhibit pro-inflammatory NFκB and AP-1 signaling in innate immune cells, 
restoring a regulatory protective phenotype (Greene et al., 2004, Butler et al., 2006, 
Taggart et al., 2005).  
Over the last years, an emerging role of WAPs in the onset and resolution of 
neuroinflammation in the CNS has been proposed (Hannila, 2014). SLPI is 
upregulated in various CNS pathologies, including animal models of multiple 
sclerosis and stroke, as well as in amyotrophic lateral sclerosis (ALS) patients 
(Mueller et al., 2008, Wang et al., 2003, Lilo et al., 2013). In addition, SLPI was 
shown to be immunomodulatory and neuroprotective in models of optic nerve and 
spinal cord injury, multiple sclerosis and stroke (Hannila et al., 2013, Ghasemlou et 
al., 2010, Mueller et al., 2008, Wang et al., 2003). We have previously identified the 
novel activated microglia/macrophage whey acidic protein (AMWAP) as a highly 
upregulated molecule in microglia from Rs1h-/Y, the FAM161A- and aSMase-deficient 
retina as well as reactive microglia and macrophages in vitro (Gehrig et al., 2007, 
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Karlstetter et al., 2010, Karlstetter et al., 2014b, Dannhausen et al., 2015). AMWAP 
is a 76 aa polypeptide containing a single WAP domain and a N-terminal signaling 
peptide for cellular export. AMWAP overexpression in cultured microglia reduces 
their pro-inflammatory gene expression, induces expression of alternative activation 
markers and reduces microglial migration, whereas RNAi-mediated AMWAP knock-
down has adverse effects (Karlstetter et al., 2010). In addition, we could recently 
show that AMWAP is actively secreted from reactive microglia in vitro to counter-
balance pro-inflammatory microglial activation through inhibition of NFκB signaling in 
a paracrine fashion (Aslanidis et al., 2015). 
 
1.3.5.3 Translocator protein (18 kDa) (TSPO) and its ligands 
The translocator protein (18 kDa) (TSPO), formerly known as peripheral 
benzodiazepine receptor (PBR), is a transmembrane protein located in the outer 
mitochondrial membrane, highly expressed in steroidogenic cells of the adrenal 
gland, gonad and brain (Papadopoulos et al., 2006, Rupprecht et al., 2010). Within 
the CNS, TSPO is expressed predominantly in glial cells and to a lesser extent in 
certain neurons, e.g. of the olfactory bulb or dorsal root ganglia sensory neurons 
(Casellas et al., 2002, Zhang et al., 2007, Karchewski et al., 2004, Maeda et al., 
2007). One of the main functions of TSPO is the cholesterol transport from the outer 
to the inner mitochondrial membrane, which is a crucial step in steroid hormone and 
neurosteroid synthesis (Papadopoulos et al., 2006). Additionally, TSPO plays a role 
in mitochondrial respiration and permeability, apoptosis and cell proliferation 
(Casellas et al., 2002, Maeda et al., 2007, Karchewski et al., 2004).  
Over the last years, many studies have surfaced observing an upregulation of TSPO 
expression during CNS pathologies (Chen and Guilarte, 2008, Rupprecht et al., 
2010). For example, TSPO expression was shown to be induced in Alzheimer’s 
disease, Huntington’s disease, Parkinson’s disease as well as in psychiatric 
disorders like anxiety or post-traumatic stress disorder (Yasuno et al., 2008, Politis et 
al., 2012, Nakamura et al., 2002, Da Pozzo et al., 2012). In a retinal context, we and 
others could recently show microglial upregulation of TSPO in the Rs1h-/Y mouse 
model of retinal degeneration, the aSMase-deficient retina as well as in an in vivo 
model of LPS-induced retinal microglia activation (Karlstetter et al., 2014a, 
Dannhausen et al., 2015, Wang et al., 2014b). The selective upregulation of TSPO in 
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microglia and astrocytes during CNS pathologies makes it a suitable biomarker to 
monitor the location, course and severity of neuroinflammatory processes. Therefore, 
TSPO serves as a target structure for neuroimaging procedures and specific TSPO 
ligands are employed as diagnostic tools e.g. for positron emission tomography 
(PET) (Chen and Guilarte, 2008). 
Since TSPO is selectively upregulated in pathologies of the CNS, in recent years 
growing interest in the use of specific TSPO ligands as a strategy to attenuate 
neuroinflammation has emerged (Rupprecht et al., 2010, Nothdurfter et al., 2012). 
TSPO has a number of endogenous ligands like cholesterol, porphyrins or 
endozepines (Li and Papadopoulos, 1998, Gavish et al., 1992, Costa and Guidotti, 
1991). Especially endozepines have been found to be highly produced during CNS 
inflammation, indicating that paracrine mechanisms of modulating glial reactivity 
through TSPO may exist. As an example, it was recently shown that Mueller cells 
and astrocytes express and secrete diazepam binding inhibitor (DBI) in the inflamed 
retina, which effectively reduces pro-inflammatory microglial cytokine expression and 
ROS secretion (Wang et al., 2014b).  
These mechanisms raised the interest in developing highly specific synthetic TSPO 
ligands as therapeutic tools to attenuate neuroinflammation. The isoquinoline 
carboxamide derivative PK11195, used as a radioligand in PET studies and the 
benzodiazepine diazepam as a classic anxiolytic drug are prime examples for 
synthetic TSPO ligands (Venneti et al., 2013, Gavish et al., 1992). It was implicated 
that TSPO ligands can act therapeutically through induction of anti-inflammatory 
cytokine and neurotrophic factor expression in microglia and protective effects have 
already been shown for ALS, neuropathic pain, brain inflammation, depression and 
anxiety disorders (Bordet et al., 2007, Wei et al., 2013, Papadopoulos and Lecanu, 
2009, Rupprecht et al., 2010). Further, TSPO ligands have been shown to reduce 
pro-inflammatory microglia reactivity and the production of pro-inflammatory 
cytokines in animal models of hippocampal and striatal brain damage (Veiga et al., 
2005, Ryu et al., 2005). Novel synthetic ligands include etifoxine (Stresam®) and 
XBD173 (Emapunil®). Etifoxine reduces neuroinflammation and is protective and 
regenerative in a mouse model of multiple sclerosis (Daugherty et al., 2013). 
XBD173 is a phenylpurine, which binds TSPO at a nanomolar affinity (Kita et al., 
2004). XBD173 was shown to possess potent anxiolytic functions in rodents and 
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humans, without exerting negative diazepam-like side effects like sedation or habit 
formation (Rupprecht et al., 2009). In addition, we could recently show that XBD173 
is a potent anti-inflammatory mediator and modulates microglial reactivity, 
neurotoxicity and phagocytosis towards a regulatory phenotype (Karlstetter et al., 
2014a). 
The exact mechanisms, through which TSPO ligands modulate microglial reactivity 
and exert their neuroprotective effects, are still largely unknown. Possible 
mechanisms include the modulation of the mitochondrial transmembrane potential, 
leading to reduced ROS production and preventing neuronal damage (Carayon et al., 
1996, Chelli et al., 2004). Another suggestion is a reduction of apoptosis-related 
caspase activation by attenuating mitochondrial cytochrome C release (Strohmeier et 
al., 2002, Veiga et al., 2005). However, since TSPO ligands increase neurosteroid 
synthesis in the CNS, which exert immunomodulatory and neuroprotective functions, 
it is likely that this could be a key mechanism of their protective action (Schule et al., 
2011). It remains to be elucidated how specific TSPO ligands fulfill their therapeutic 
function in detail, and it is likely that a combination of the described effects 
contributes to their effectiveness. 
 
1.4 Aims of the thesis 
In a comprehensive approach, we focused on the understanding of photoreceptor 
homeostasis and disease mechanisms, the identification and characterization of 
novel microgliosis markers as well as potential future therapeutics in neuro-
degenerative diseases with an emphasis on microglia-directed anti-inflammatory 
therapy in the brain and retina. 
Thus, one aim of this work was to investigate the novel CRX-regulated gene SAMD7 
in the retina. Elucidating its spatiotemporal expression pattern, the exact regulatory 
fine-tuning of SAMD7 by the photoreceptor-specific transcription factor CRX and the 
putative function of SAMD7 as a repressor of CRX-mediated photoreceptor gene 
expression, we aimed to gain understanding into the fine-tuning of photoreceptor 
homeostasis and potential disease mechanisms of inherited retinal degenerations. 
Another goal was to elucidate the paracrine anti-inflammatory potential of the novel 
activated microglia/macrophage whey acidic protein (AMWAP) in microglial cells. 
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Using recombinant AMWAP, we sought to shed light on AMWAPs effects on 
microglial NFκB signaling and classical physiological functions of microglia in vitro, 
with the aim of establishing whey acidic proteins as potential future therapeutics in 
neurodegenerative diseases of the brain and retina. 
Finally, we were interested in the role of the translocator protein (18 kDa) (TSPO) in 
the context of neuroinflammation in the retina. Investigating its potential as a novel 
biomarker for pro-inflammatory microglia activation in the degenerating retina and 
employing the specific TSPO ligand XBD173 to modulate microglial reactivity in vitro 
and ex vivo, we aimed to establish TSPO as a potential target structure for microglia-
directed anti-inflammatory therapy in the brain and retina. 




2.1 Sterile alpha motif containing 7 (SAMD7) is a novel 
CRX-regulated transcriptional repressor in the retina 
Julia Hlawatsch*, Marcus Karlstetter*, Alexander Aslanidis*, Anika Lückoff, Yana Walczak, 
Michael Plank, Julia Böck, and Thomas Langmann  
*these authors contributed equally 
Inherited retinal diseases are mainly caused by mutations in genes that are highly 
expressed in photoreceptors of the retina. The majority of these genes is under the 
control of the transcription factor Cone rod homeobox (CRX), which acts as a master 
transcription factor in photoreceptors. Using a genome-wide chromatin immuno-
precipitation dataset that highlights all potential in vivo targets of CRX, we have 
identified a novel sterile alpha motif (SAM) domain containing protein, SAMD7. 
mRNA Expression of SAMD7 was confined to the late postnatal and adult mouse 
retina as well as the pineal gland. Using immunohistochemistry and Western blot, we 
could detect SAMD7 protein in the outer nuclear layer of adult mouse retina. Ectopic 
over-expression in HEK293 cells demonstrated that SAMD7 resides in the cytoplasm 
as well as the nucleus. In vitro electroporation of fluorescent reporters into living 
mouse retinal cultures revealed that transcription of the SAMD7 gene depends on 
evolutionary conserved CRX motifs located in the first intron enhancer. Moreover, 
CRX knock-down with shRNA strongly reduced SAMD7 reporter activity and 
endogenous SAMD7 protein, indicating that CRX is required for retinal expression of 
SAMD7. Finally, using co-transfections in luciferase reporter assays we found that 
SAMD7 interferes with CRX-dependent transcription. SAMD7 suppressed luciferase 
activity from a reporter plasmid with five CRX consensus repeats in a dose 
dependent manner and reduced CRX-mediated transactivation of regulatory 
sequences in the retinoschisin gene and the SAMD7 gene itself. Taken together, we 
have identified a novel retinal SAM domain protein, SAMD7, which could act as a 
transcriptional repressor involved in fine-tuning of CRX-regulated gene expression. 
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Own contribution to publication I: 
I carried out the characterization of the novel SAMD7 gene by analyzing its tissue-
specific mRNA expression (Fig. 2 B) and its expression in the pineal gland (Fig. 2 C). 
I further elucidated the retina-specific localization of SAMD7 protein to the 
photoreceptor layer using immunohistochemistry (Fig. 3 A). Further, I established, 
designed, performed and analyzed ex vivo electroporation knock-down experiments 
in murine retinal explants combined with immunohistochemistry to show the CRX-
dependent regulation and expression of SAMD7 (Fig. 5 A,B). Finally, I demonstrated 
the important transcriptional repression function of SAMD7 using Luciferase reporter 
assays in HEK293 cells, after optimizing the protocol (Fig. 6 A-D). I co-supervised 
Bachelor student Michael Plank, who also contributed experimentally to this project. 
All images depicting my experimental data were created by me. I presented posters 
and oral presentations as first author on this project at both national and international 
symposia during my PhD. 
 
Contribution of co-authors to publication I: 
Dr. Julia Hlawatsch was a medical student, who participated in the early stages of the 
project and helped to establish anti-SAMD7 immunohistochemistry. Dr. Marcus 
Karlstetter carried out bioinformatic analysis (Fig. 1 A-D) and characterization of the 
SAMD7 protein, helped with dissection of pineal glands and carried out Flag-SAMD7 
transfections and immunocytochemistry in HEK293 cells (Fig. 3 E-P). Anika Lückoff 
cloned the Flag-SAMD7 construct, carried out transfection of HEK293 cells and 
Western blot analysis (Fig. 3 B-D). Yana Walczak carried out SAMD7 qRT-PCR of 
postnatal murine retinas (Fig. 2 D). Michael Plank and Julia Böck performed ex vivo 
electroporation of SAMD7 reporter constructs into living mouse retinas under my co-
supervision (Fig. 4 C-E). Prof. Thomas Langmann, as principal investigator, 
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2.2 Activated microglia/macrophage whey acidic protein 
(AMWAP) inhibits NFκB signaling and induces a 
neuroprotective phenotype in microglia 
Alexander Aslanidis, Marcus Karlstetter, Rebecca Scholz, Sascha Fauser, Harald Neumann, 
Cora Fried, Markus Pietsch* and Thomas Langmann* 
*these authors contributed equally 
Background: Microglia reactivity is a hallmark of neurodegenerative diseases. We 
have previously identified activated microglia/macrophage whey acidic protein 
(AMWAP) as a counter-regulator of pro-inflammatory response. Here, we studied its 
mechanisms of action with a focus on toll-like receptor (TLR) and nuclear factor κB 
(NFκB) signaling. 
Methods: Recombinant AMWAP was produced in Escherichia coli and HEK293 
EBNA cells and purified by affinity chromatography. AMWAP uptake was identified 
by fluorescent labeling, and pro-inflammatory microglia markers were measured by 
qRT-PCR after stimulation with TLR ligands. NFκB pathway proteins were assessed 
by immunocytochemistry, Western blot, and immunoprecipitation. A 20S proteasome 
activity assay was used to investigate the anti-peptidase activity of AMWAP. 
Microglial neurotoxicity was estimated by nitrite measurement and quantification of 
caspase 3/7 levels in 661W photoreceptors cultured in the presence of microglia-
conditioned medium. Microglial proliferation was investigated using flow cytometry, 
and their phagocytosis was monitored by the uptake of 661W photoreceptor debris. 
Results: AMWAP was secreted from lipopolysaccharide (LPS)-activated microglia 
and recombinant AMWAP reduced gene transcription of IL6, iNOS, CCL2, CASP11, 
and TNFα in BV-2 microglia treated with LPS as TLR4 ligand. This effect was 
replicated with murine embryonic stem cell-derived microglia (ESdM) and primary 
brain microglia. AMWAP also diminished pro-inflammatory markers in microglia 
activated with the TLR2 ligand zymosan but had no effects on IL6, iNOS, and CCL2 
transcription in cells treated with CpG oligodeoxynucleotides as TLR9 ligand. 
Microglial uptake of AMWAP effectively inhibited TLR4-dependent NFκB activation by 
preventing IRAK-1 and IκBα proteolysis. No inhibition of IκBα phosphorylation or 
ubiquitination and no influence on overall 20S proteasome activity were observed. 
Functionally, both microglial nitric oxide (NO) secretion and 661W photoreceptor 
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apoptosis were significantly reduced after AMWAP treatment. AMWAP promoted the 
filopodia formation of microglia and increased the phagocytic uptake of apoptotic 
661W photoreceptor cells. 
Conclusions: AMWAP is secreted from reactive microglia and a acts in a paracrine 
fashion to counter-balance TLR2/TLR4-induced reactivity through NFκB inhibition. 
AMWAP also induces a neuroprotective microglial phenotype with reduced 
neurotoxicity and increased phagocytosis. We therefore hypothesize that anti-
inflammatory whey acidic proteins could have a therapeutic potential in 
neurodegenerative diseases of the brain and the retina. 
 
Own contribution to publication II: 
This was one of my main DFG-funded PhD projects. I designed, performed and 
analyzed all experiments, assisted with CFSE-proliferation assays, created all 
images except CFSE-proliferation assay image, which I finalized, and wrote the 
manuscript draft. I independently handled the revision phase of this project. I 
presented posters and oral presentations on this project at both national and 
international symposia during my PhD. 
 
Contribution of co-authors to publication II: 
Dr. Marcus Karlstetter provided the AMWAP-His expression plasmid and the 
previously created AMWAP antibody, further he provided suggestions towards 
possible experimental strategies. Rebecca Scholz established, performed and 
analyzed CFSE-proliferation experiments using flow cytometry and created the 
image (Fig. 10 B). Prof. Sascha Fauser provided suggestions and critically read the 
manuscript. Prof. Harald Neumann provided embryonic stem cell-derived microglia. 
Dr. Markus Pietsch and Cora Fried introduced me to recombinant protein expression 
and purification from HEK293 EBNA cells, which I then carried out in their laboratory. 
Prof. Thomas Langmann, as principal investigator, obtained funding, supervised the 
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2.3 Translocator protein (18 kDa) (TSPO) is expressed in 
reactive retinal microglia and modulates microglial 
inflammation and phagocytosis 
Marcus Karlstetter*, Caroline Nothdurfter*, Alexander Aslanidis, Katharina Moeller, Felicitas 
Horn, Rebecca Scholz, Harald Neumann, Bernhard H F Weber, Rainer Rupprecht* and 
Thomas Langmann*  
*these authors contributed equally 
Background: The translocator protein (18 kDa) (TSPO) is a mitochondrial protein 
expressed on reactive glial cells and a biomarker for gliosis in the brain. TSPO 
ligands have been shown to reduce neuroinflammation in several mouse models of 
neurodegeneration. Here, we analyzed TSPO expression in mouse and human 
retinal microglia and studied the effects of the TSPO ligand XBD173 on microglial 
functions. 
Methods: TSPO protein analyses were performed in retinoschisin-deficient mouse 
retinas and human retinas. Lipopolysaccharide (LPS)-challenged BV-2 microglial 
cells were treated with XBD173 and TSPO shRNAs in vitro and pro-inflammatory 
markers were determined by qRT-PCR. The migration potential of microglia was 
determined with wound healing assays and the proliferation was studied with 
Fluorescence Activated Cell Sorting (FACS) analysis. Microglial neurotoxicity was 
estimated by nitrite measurement and quantification of caspase 3/7 levels in 661 W 
photoreceptors cultured in the presence of microglia-conditioned medium. The 
effects of XBD173 on filopodia formation and phagocytosis were analyzed in BV-2 
cells and human induced pluripotent stem (iPS) cell-derived microglia (iPSdM). The 
morphology of microglia was quantified in mouse retinal explants treated with 
XBD173. 
Results: TSPO was strongly up-regulated in microglial cells of the dystrophic mouse 
retina and also co-localized with microglia in human retinas. Constitutive TSPO 
expression was high in the early postnatal Day 3 mouse retina and declined to low 
levels in the adult tissue. TSPO mRNA and protein were also strongly induced in 
LPS-challenged BV-2 microglia while the TSPO ligand XBD173 efficiently 
suppressed transcription of the pro-inflammatory marker genes chemokine (C-C 
motif) ligand 2 (CCL2), interleukin 6 (IL6) and inducible nitric oxide (NO)-synthase 
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(iNOS). Moreover, treatment with XBD173 significantly reduced the migratory 
capacity and proliferation of microglia, their level of NO secretion and their neurotoxic 
activity on 661 W photoreceptor cells. Furthermore, XBD173 treatment of murine and 
human microglial cells promoted the formation of filopodia and increased their 
phagocytic capacity to ingest latex beads or photoreceptor debris. Finally, treatment 
with XBD173 reversed the amoeboid alerted phenotype of microglial cells in 
explanted organotypic mouse retinal cultures after challenge with LPS. 
Conclusions: These findings suggest that TSPO is highly expressed in reactive 
retinal microglia and a promising target to control microglial reactivity during retinal 
degeneration. 
 
Own contribution to publication III: 
This was another important project, for which I obtained funding through a PhD 
scholarship by the Pro Retina Germany foundation. I carried out the spatiotemporal 
expression analysis and characterization of TSPO as a marker for microgliosis in the 
retina using immunohistochemistry (Fig. 1 A-I), quantitative real-time PCR and 
Western blot (Fig. 2 A-E) on various samples. I further established, performed and 
analyzed scratch wound healing assays (Fig. 4 A, B) and phenotyping of microglial 
morphology using Phalloidin-TRITC staining (Fig. 5 A-D). In addition, I established, 
performed and analyzed microglial phagocytosis assays employing either latex 
beads or apoptotic photoreceptor fragments as bait (Fig. 6 A-D). I supervised Master 
student Felicitas Horn, who also contributed experimentally during the revision phase 
of this publication. All images depicting my experimental data were created by me. I 
presented posters and oral presentations as first author on this project at both 
national and international symposia during my PhD. 
 
Contribution of co-authors to publication III: 
Dr. Marcus Karlstetter conceptualized parts of the project, finalized images, managed 
collaborations and carried out qRT-PCR analysis and neurotoxicity assays to show 
the anti-inflammatory effect of the TSPO ligand XBD173 (Fig. 3 A-H). Dr. Caroline 
Nothdurfter carried out pregnenolone ELISA (Fig. 7 A). Katharina Moeller performed 
aminoglutethimide phagocytosis assays (Fig. 7 B) and optimized and carried out 
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retinal explant experiments (Fig. 8 A-E). Felicitas Horn, under my supervision, 
performed Phalloidin staining and phagocytosis assays using iPSdM cells (Fig. 5 E-
H, Fig. 6 E-H). Rebecca Scholz established, performed and analyzed TSPO/GFAP 
and TSPO/MAP2 immunohistochemistry as well as CFSE-proliferation assays (Fig. 1 
J-M, Fig. 4 C). Prof. Harald Neumann provided iPSdM cells. Prof. Bernhard Weber 
provided valuable suggestions and critically read the manuscript. Prof. Rainer 
Rupprecht supplied the synthetic TSPO ligand XBD173 and provided valuable 
suggestions. Prof. Thomas Langmann, as principal investigator, coordinated the 
project and wrote the manuscript. 
 




3.1 Results from the three presented studies in summary 
1. Sterile alpha motif containing 7 (SAMD7) is expressed in retinal 
photoreceptors and the pineal gland and its expression is regulated by the 
photoreceptor key transcription factor CRX. SAMD7 localizes to the cytosol 
and nucleus and acts as a transcriptional repressor of CRX-mediated 
photoreceptor gene expression. 
2. Activated microglia/macrophage whey acidic protein (AMWAP) is actively 
secreted from reactive microglia and reduces TLR-mediated pro-inflammatory 
gene expression through inhibition of NFκB signaling in a paracrine fashion. 
AMWAP further reduces microglial neurotoxicity, promotes filopodia formation 
and increases microglial phagocytosis in vitro, typical hallmarks of a regulatory 
phenotype. 
3. The translocator protein (18 kDa) (TSPO) is a biomarker for microglial 
reactivity in the dystrophic mouse retina and also expressed in human retinal 
microglia. It is further induced in reactive microglia in vitro. The specific TSPO 
ligand XBD173 effectively reduces pro-inflammatory microglial gene 
expression, proliferation, migration and neurotoxicity in vitro. XBD173 further 
induces filopodia formation and increases microglial phagocytosis in murine 
and human microglia. Finally, XBD173 reduces the number of pro-
inflammatory amoeboid microglia in ex vivo organotypic murine retinal explant 
cultures.  
 
3.2 SAMD7, a novel photoreceptor gene repressor 
In the first study, we could identify SAMD7 as a novel CRX-regulated photoreceptor-
specific gene, which acts as a repressor of CRX-mediated photoreceptor gene 
transcription (Hlawatsch et al., 2013). SAMD7 is the hitherto second SAM domain 
containing protein next to its closest phylogenetic relative SAMD11. SAMD7 and 
SAMD11 show a similar spatiotemporal expression profile in photoreceptors and the 
pineal gland. SAMD11 was previously also described to act as a repressor of CRX-
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dependent photoreceptor gene expression (Inoue et al., 2006). Since this family of 
proteins is known to interact through their SAM domains (Kim and Bowie, 2003), it 
will be interesting to investigate whether SAMD7 and SAMD11 interact to modulate 
photoreceptor gene expression in a combinatorial fashion. 
 
3.2.1 Photoreceptor-specific SAMD7 gene regulation 
CRX ChIP-seq revealed SAMD7 to be strongly CRX-regulated by binding CRX in the 
promoter and first intron (CBR1 and CBR2). Interestingly, the promoter CBR (CBR1) 
alone was not sufficient to induce reporter expression in the ex vivo electroporation 
experiments and required the presence of the enhancing CBR2. CBR2 contains two 
crucial individual CRX binding sites (CBS), which exhibit the perfect CRX consensus 
sequence (5’-GATTA-3’), as previously identified from over 5,595 CRX-bound 
regions (Corbo et al., 2010). These findings strengthen the notion that photoreceptor-
specific genes, including most disease genes, are tightly regulated by a number of 
cis-regulatory elements binding CRX. In addition, SAMD7 was shown to be NRL-
regulated, as NRL binds to the same cis-regulatory regions as CRX (Hao et al., 2012, 
Aslanidis et al., 2013). In further experiments, we could indeed verify a reduced 
enhancer activity of SAMD7 CBR2 as well as reduced SAMD7 protein levels in 
photoreceptors after NRL knock-down using ex vivo electroporation into living mouse 
retinas (Aslanidis et al., 2013). CRX is known to synergistically interact with NRL to 
regulate photoreceptor-specific gene expression in many cases (Mitton et al., 2000). 
It is therefore not clear if the observed SAMD7 downregulation after NRL knock-down 
is solely due to reduced NRL-mediated SAMD7 transcription or a combinatorial 
effect. Interestingly, SAMD7 mRNA levels are strongly reduced in the OTX2-deficient 
retina (Omori et al., 2011). However, it is also unclear if SAMD7 is directly regulated 
by OTX2 or the loss of SAMD7 expression is a secondary effect due to reduced CRX 
levels in OTX2-deficient photoreceptors. Further experiments will be helpful in 
deciphering the exact cis-regulatory architecture of the SAMD7 gene. 
 
3.2.2 SAMD7, a gene regulator without DNA binding sequence 
Functionally, using Luciferase assays we could show that SAMD7 interferes with the 
CRX-mediated gene transcription at photoreceptor-specific promoters. This is 
  3. Discussion 
37 
 
particularly interesting, as SAMD7 lacks an obvious DNA binding domain. The 
drosophila SAM domain protein Mae, also carrying a single SAM domain and lacking 
a DNA binding domain, interacts with the SAM domain of the transcriptional 
repressor Yan which leads to a termination of repressor activity by translocation to 
the cytoplasm (Baker et al., 2001, Qiao et al., 2004). It is therefore imaginable that 
SAMD7 exerts its repressor function by forming non-active protein complexes with 
CRX. SAMD7 could also fulfil its function through chromatin remodeling, as the SAM 
domain containing PRC2 (polycomb repressive complex 2) has been shown to 
silence gene expression through this mechanism (Aldiri and Vetter, 2012). Recently, 
another repressor of CRX-mediated photoreceptor gene expression, PANKY-A, was 
identified, which inhibits the DNA binding activity of CRX (Sanuki et al., 2010). 
Further analyses will be required to reveal the exact mechanisms of SAMD7 
repressor function. We could so far show that SAMD7 represses gene transcription 
from three different CRX-dependent promoters. Future experiments employing 
SAMD7-deficient or knock-down retinas will be particularly helpful in identifying a 
comprehensive list of in vivo target genes affected by SAMD7. 
 
3.2.3 Potential role of SAMD7 in retinal health and disease 
In an ongoing collaborative effort, we and others could recently identify mutations of 
regulatory CRX target regions in the SAMD7 gene in a family of retinitis pigmentosa 
patients (Van Schil et al., 2015). Ex vivo electroporation and luciferase reporter 
assays show a significant loss of cis-regulatory activity of the mutant sequences. This 
is the first description of regulatory SAMD7 mutations in humans, which could have a 
potential modifying effect on the observed disease phenotype. Of note, a recent 
study reports the presence of multiple SAMD11 alternative splice variants in the 
human retina (Jin et al., 2013). It will be interesting to focus research on SAMD7 also 
in this regard and potentially identify novel splice variants with different functions in 
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3.3 AMWAP, a counter-regulator of microglial reactivity 
In the second study, we could demonstrate that the activated microglia/macrophage 
whey acidic protein (AMWAP) is actively secreted from reactive microglia to reduce 
pro-inflammatory microglial activation in a paracrine fashion and therefore serves as 
a negative feedback-loop to counter-regulate neuroinflammation (Aslanidis et al., 
2015). Recombinant AMWAP elicits this effect through inhibition of NFκB signaling 
and induces an overall neuroprotective phenotype in microglia in vitro. 
 
3.3.1 Obtaining recombinant AMWAP for therapy 
We observed a rapid induction and secretion of AMWAP after LPS stimulation of 
microglial cells in vitro. This notion is in coherence with the transcriptional control of 
the AMWAP gene by NFκB, as we could previously show that blockade of NFκB 
signaling inhibits TLR4-mediated AMWAP expression (Karlstetter et al., 2010). This 
finding prompted us to investigate the physiological functions of recombinantly 
expressed AMWAP with a focus on its microglia-modulating therapeutic potential. 
When producing potential anti-inflammatory mediators through recombinant protein 
expression and purification, we observed that it is more feasible to employ a 
eukaryotic organism like HEK293 EBNA cells for expression, as a prokaryotic source 
like E. coli bears the risk of LPS contamination of the purified protein, which leads to 
high immunogenicity. In addition, proper protein folding and disulfide bond formation 
are also ensured when using eukaryotic expression systems as previously 
demonstrated for the whey acidic protein SLPI expressed in the yeast Pichia pastoris 
(Li et al., 2009, Li et al., 2010). 
 
3.3.2 AMWAP, an inhibitor of microglial NFκB signaling 
We could show that recombinant AMWAP is gradually being taken up by microglial 
cells and localizes to the cytoplasm in a patchy perinuclear fashion, an observation 
reminiscent of SLPI in neutrophils (Jacobsen et al., 2008). In contrast to SLPI, which 
was previously described by Taggart and colleagues to also act in the nucleus by 
inhibiting NFκB binding to its pro-inflammatory gene promoters, we did not observe 
any nuclear uptake of AMWAP in microglia (Taggart et al., 2005). AMWAP inhibits 
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NFκB signaling and effectively reduces TLR2- and TLR4-mediated pro-inflammatory 
gene expression in microglia cells from different sources in vitro. The lack of this 
effect when cells are activated through TLR9 signaling could be due to the fact that 
TLR2 and TLR4 signal mainly through NFκB, which is effectively inhibited by 
AMWAP, but TLR9 signals majorly through interferon regulatory factors (IRFs) 
(O'Neill et al., 2013). These findings are in coherence with the report of SLPI 
inhibiting pro-inflammatory TLR2 and TLR4 responses in human monocytes (Greene 
et al., 2004).  
Mechanistically we could show that AMWAP exerts its NFκB inhibitory effect through 
blocking the proteolytic degradation of the NFκB pathway mediators IRAK-1 and IκBα 
without affecting IκBα phosphorylation, ubiquitination or any of the 20S proteasome 
peptidase activities directly. A similar function has been described for the whey acidic 
proteins SLPI and elafin in monocytes as well as for the antibacterial peptide PR39, 
where IκBα gets labeled properly for proteolytic degradation but does not get cleaved 
by the proteasome, therefore keeping its NFκB regulatory function (Taggart et al., 
2002, Butler et al., 2006, Gao et al., 2000). There is conflicting evidence whether the 
NFκB inhibitory effect of whey acidic proteins is dependent on the anti-protease 
activity of their WAP domain (Williams et al., 2006, Yang et al., 2005). Future 
experiments will have to show which elements of AMWAP are accountable for its 
anti-inflammatory function. 
 
3.3.3 AMWAP induces a neuroprotective microglial phenotype 
Functionally we could show that AMWAP induces a regulatory neuroprotective 
phenotype in microglia in vitro. AMWAP significantly reduces microglial NO secretion 
and neurotoxicity on photoreceptor cells. In coherence with these findings, SLPI 
overexpression was previously shown to reduce macrophage NO secretion (Jin et 
al., 1997, Yang et al., 2005). In addition, SLPI reduces LPS-induced neutrophil 
apoptosis while a lack of SLPI leads to increased apoptosis of myeloid cells 
(Subramaniyam et al., 2011, Klimenkova et al., 2014).  
We could demonstrate that AMWAP induces a ramified microglial phenotype, and 
even reverses the pro-inflammatory amoeboid phenotype observed after LPS 
stimulation, which is regarded as an anti-inflammatory feature (Nimmerjahn et al., 
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2005). Further, the recognition and phagocytic clearance of apoptotic cell debris is 
also a typical characteristic of a regulatory microglial phenotype (Sierra et al., 2013, 
Karlstetter et al., 2014a). In line with this, we could show increased phagocytic 
uptake of apoptotic photoreceptor cells by AMWAP-treated microglia, regardless of 
further LPS stimulation, as apoptotic cells alone serve as an activatory stimulus for 
microglia (Heneka et al., 2014). Interestingly, elafin was previously shown to protect 
macrophages from degradation of their receptors for apoptotic cell recognition, 
effectively restoring their phagocytic activity and clearance potential, and a similar 
mechanism can be imagined for AMWAP (Henriksen et al., 2004). 
Increased proliferation rates are a typical hallmark of reactive microglia (Perry et al., 
2010, Chen and Guilarte, 2008). However, we did not observe an anti-mitotic effect 
of AMWAP on microglial cells. It is noteworthy that there is conflicting evidence in the 
literature regarding the anti-proliferative potential of WAPs with one study even 
showing a SLPI-induced increase in stem cell proliferation towards an oligo-
dendroglial cell fate via induction of Cyclin D1 (Mueller et al., 2008). Future 
experiments employing ex vivo organotypic retinal explant cultures or in vivo models 
of retinal degeneration will be needed to potentially translate the AMWAP-induced 
beneficial regulatory microglia phenotype into living tissues. 
 
3.3.4 AMWAP, current state and future perspectives 
In sum, our studies on the novel activated microglia/macrophage whey acidic protein 
(AMWAP) as a marker and modulator of pro-inflammatory microglial activation have 
enabled us to gain insight into mechanisms of microglial reactivity in neuro-
inflammatory settings (Karlstetter et al., 2010, Aslanidis et al., 2015). Today, we 
employ AMWAP as a reliable bona fide transcriptional biomarker to monitor microglial 
activation states in various genetic or light-induced retinal degenerative mouse 
models as well as in vitro (Karlstetter et al., 2014b, Dannhausen et al., 2015). We 
could show that AMWAP is secreted from pro-inflammatory microglia and serves as a 
negative feedback-loop to counter-regulate microglial reactivity. Future experiments 
using recombinant AMWAP or AAV-mediated AMWAP overexpression in the retina 
of murine retinal degeneration models will have to demonstrate the therapeutic value 
of whey acidic proteins as a microglia-directed immunotherapy in neurodegenerative 
diseases. 
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3.4 TSPO, emerging roles in the CNS and retina  
In the third study, we could establish the translocator protein (18 kDa) (TSPO) as a 
novel biomarker for reactive microgliosis in the degenerating retina as well as in vitro 
(Karlstetter et al., 2014a). Treatment of murine and human microglia with the specific 
synthetic TSPO ligand XBD173 effectively reduces microglial reactivity and induces a 
neuroprotective phenotype in vitro. In addition, XBD173 effectively reduces the 
number of LPS-induced reactive amoeboid microglia in organotypic ex vivo retinal 
explant cultures. 
 
3.4.1 TSPO, a novel marker for reactive retinal microglia 
We and others present the first report of TSPO as a marker for reactive microglia 
during retinal degeneration (Karlstetter et al., 2014a, Wang et al., 2014b). The 
observed elevated microglial TSPO protein levels are in perfect overlap with the 
course of microglia activation in the Rs1h-/- mouse model (Karlstetter et al., 2010). 
Since we also observed an upregulation of TSPO in LPS-activated microglial cells in 
vitro, a potential TLR4-mediated mechanism of induction can be imagined. In line 
with this, blockade of TLR4 signaling was shown to inhibit TSPO induction in a rat 
model of neuropathic pain (Wei et al., 2013). It is therefore imaginable, that damage-
associated molecular patterns (DAMPs) from dying neurons could induce TSPO 
expression through stimulating TLR4 on microglia (Frank et al., 2015). We also 
observed a peak of TSPO mRNA levels in the healthy early postnatal (P3) retina 
before decline to basal levels in the adult retina. This is in accordance with the notion 
that microglia are initially mitotic, amoeboid and phagocytically active in early 
postnatal neuronal development, before they gradually adopt their ramified and 
surveillant phenotype (Prinz and Mildner, 2011, Schlegelmilch et al., 2011). Our 
findings expand the use of TSPO as a potential microgliosis biomarker, e.g. for 
radiolabeling and live imaging techniques, from the brain to the retinal context 
(Trapani et al., 2013). In addition, we could very recently demonstrate an increase of 
TSPO expression in reactive retinal microglia in the aSMase-deficient mouse model 
(Dannhausen et al., 2015). Future analyses of various genetic or induced retinal 
degeneration animal models will have to prove the reliability of assessing retinal 
microgliosis through TSPO quantification.  
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3.4.2 Functions of TSPO and its ligands in reactive microglia 
We could show various anti-inflammatory effects of the synthetic TSPO ligand 
XBD173 on microglial cells in vitro and ex vivo. XBD173 effectively reduces LPS-
induced pro-inflammatory gene expression in microglia, an effect also observed for 
the TSPO ligand PK11195 via modulation of Ca2+-mediated signaling pathways (Choi 
et al., 2002). PK11195 further proved to be anti-inflammatory and neuroprotective in 
a rat model of quinolinic acid-induced brain damage (Ryu et al., 2005). We could 
show that the reduced pro-inflammatory gene expression in microglia after XBD173 
treatment is indeed dependent on TSPO, as shRNA-mediated TSPO knock-down 
abolished the therapeutic effect (Karlstetter et al., 2014a). 
A potential mechanism by which XBD173 acts anti-inflammatory could be through 
inhibition of NFκB and AP-1 signaling, as another TSPO ligand, vinpocetine, was 
previously shown to reduce pro-inflammatory cytokine production and neurotoxicity in 
microglia in vitro and in vivo in this fashion (Zhao et al., 2011, Wang et al., 2014a). 
Another potential mechanism by which XBD173 exerts its anti-inflammatory function 
could be by elevating neurosteroid production. Indeed, we could show that XBD173 
enhances the synthesis of the neurosteroid precursor pregnenolone in microglial 
cells in vitro and another TSPO ligand, etifoxine, exerts a similar effect in the rat brain 
(Karlstetter et al., 2014a, Verleye et al., 2005). In addition, elevated neurosteroid 
levels were shown to be protective in animal models of motoneuron degradation and 
multiple sclerosis (Ferzaz et al., 2002, Giatti et al., 2012).  
We observed an induction of microglial filopodia formation after treating murine and 
human microglia with XBD173, a typical hallmark of homeostatic microglia. A 
potential mechanism, through which XBD173 exerts its effects on the microglial f-
actin cytoskeleton, could be by modulation of intracellular Ca2+ signaling. It was 
previously described that LPS stimulation of microglia and neutrophils leads to an 
increase in cytosolic Ca2+ and subsequent remodeling of the f-actin cytoskeleton 
(Bader et al., 1994, Yee and Christou, 1993). Interestingly, PK11195 reduces the 
LPS-induced elevation of Ca2+ levels, which is generally considered a hallmark of 
regulatory microglia (Hong et al., 2006, Choi et al., 2002).  
We could demonstrate increased TSPO expression, migration and proliferation in 
LPS-activated microglial cells in vitro, which was effectively reduced after XBD173 
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treatment. In accordance, TSPO overexpression was shown to increase migration 
and proliferation of C6 rat glioma cells and treatment with the TSPO ligand PK11195 
exerts a strong anti-proliferative and pro-apoptotic effect on these cells (Rechichi et 
al., 2008). A potential mechanism by which XBD173 executes its effects on microglia 
migration and proliferation could be by modulation of phosphatidylinositol-3 kinase 
(PI3K) signaling or Ca2+-dependent protein kinase C (PKC) activation, two events 
that were previously shown to be influenced by TSPO and its ligands (Venneti et al., 
2007, Azarashvili et al., 2007, Batarseh et al., 2010). Activation of either PI3K or PKC 
has been implicated in the signaling cascade associated with the migratory and 
proliferative activity of microglia (Suh et al., 2005, Zassler et al., 2003). In addition to 
these findings, other TSPO ligands have previously been shown to influence 
chemotactic and phagocytic behavior in monocytes and neutrophils (Ruff et al., 1985, 
Cosentino et al., 2000, Marino et al., 2001).  
We could also show a XBD173-induced elevation of microglial phagocytic clearance 
of both latex beads and apoptotic photoreceptor debris. Interestingly, blockade of 
pregnenolone synthesis using aminoglutethimide (AMG) reversed this effect 
(Karlstetter et al., 2014a). This indicates neurosteroid synthesis being a prerequisite 
for microglial phagocytosis in our experimental system. Interestingly, estrogen was 
previously shown to enhance phagocytosis of amyloid-β in human cortical microglia 
cultures (Li et al., 2000). Accordingly, another study also observed increased 
phagocytic clearance by microglia after treatment with the TSPO ligands PK11195 
and Ro-4864 (Choi et al., 2011). As introduced above, activation of PI3K and PKC 
have been implicated in the signaling cascade associated with the phagocytic activity 
of macrophages and microglia (Makranz et al., 2004, Cohen et al., 2006, Rotshenker 
et al., 2008).  
We observed a significantly reduced number of LPS-alerted amoeboid microglia in 
living retinal explants after treatment with XBD173. Interestingly, however, the overall 
fraction of ramified cells was not increased by XBD173. These findings indicate that 
TSPO may control microglial dynamics and behavior during the onset and resolution 
of retinal damage. Within the retina, endogenous ligands (endozepines) may serve 
as TSPO-directed modulators of microglial reactivity to fulfil this function. One 
example is the diazepam binding inhibitor (DBI), which was previously shown to be 
actively secreted from Mueller cells and astrocytes (Wang et al., 2014b, Alho et al., 
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1994). DBI then acts through TSPO to reduce pro-inflammatory microglial ROS 
production, cytokine expression and secretion as well as proliferation (Wang et al., 
2014b). Further, DBI can be cleaved into several active peptide fragments which then 
stimulate neurosteroid synthesis (Costa et al., 1994). 
 
3.4.3 TSPO, current state and future perspectives 
With TSPO fulfilling a multitude of different functions in many different cell types, 
including glial cells of the CNS, there is a growing interest in revealing its functions in 
the context of health and disease. For this purpose, various approaches of 
generating and characterizing TSPO-deficient mouse models have been undertaken 
over the last couple of years (Gut et al., 2015). First attempts of generating TSPO-/- 
mice reported early embryonal lethality, implicating vital potentially steroidogenic 
functions of TSPO during embryogenesis (Papadopoulos et al., 1997). In heavy 
contrast, recent studies of novel TSPO knock-out mouse strains could not confirm a 
crucial role of TSPO in steroid synthesis, mitochondrial permeability, survival or 
reproduction (Banati et al., 2014, Sileikyte et al., 2014, Tu et al., 2014, Morohaku et 
al., 2014, Tu et al., 2015). These observations call for a reassessment of the 
dogmatic indispensable importance of TSPO for life in general (Campanella, 2015). 
Interestingly, however, it was reported that microglial cells from a global TSPO 
knock-out mouse line show significantly reduced mitochondrial ATP production, 
suggesting reduced metabolic activity and potential effects on microglial behavior in 
the healthy and degenerating CNS (Banati et al., 2014, Rodriguez et al., 2013). 
Future experiments employing microglia-specific conditional TSPO knock-out mice 
will therefore be valuable tools to assess the functions of TSPO in the healthy and 
degenerating CNS and retina. 
We observed a potentially NFκB-mediated induction of TSPO expression in microglial 
cells and bioinformatic analysis revealed a putative NFκB binding site in the TSPO 
promoter region. As TSPO is expressed in a multitude of different tissues and cells, a 
variety of transcription factors were found to bind to its promoter. The TATA-less, 
GC-rich promoter contains five tandem binding sites for Sp factors, a typical 
characteristic of housekeeping genes (Batarseh and Papadopoulos, 2010). However, 
a similar structure is found in growth factor receptor genes important for cell 
proliferation (DiMario, 2002). Mechanisms of TSPO induction include the PKC-
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mediated activation of the mitogen-activated protein kinase (MAPK) and signal 
transducer and activator of transcription 3 (STAT3) (Batarseh et al., 2010). Ongoing 
investigations on microglia-specific transcriptional TSPO regulation in homeostatic 
and reactive states will shed light on mechanisms of TSPO induction during 
neuroinflammation. 
In summary, we present the first report of TSPO as a microglial biomarker and 
potential therapeutic target to attenuate neuroinflammation in retinal degeneration. 
Future experiments employing TSPO ligands like XBD173 as microglia-directed 
therapy in animal models of retinal degeneration will have to prove their feasibility as 
a novel treatment option. 
 
3.5 Concluding remarks 
Loss of vision due to inherited retinal degeneration is a devastating and in most 
cases unstoppable prognosis and accompanied by large constraints in the life quality 
of affected patients. In our studies, we contribute to the understanding of retinal 
homeostasis in health and disease by characterization of the novel photoreceptor 
gene regulator SAMD7, which could have future implications as an elicitor or 
modulator of retinal degenerative phenotypes. 
Neuroinflammation and reactive microgliosis are common hallmarks and early 
indicators of retinal degeneration, and chronic neurotoxic microglial reactivity has 
detrimental effects and contributes to disease progression. Therefore, there is a high 
interest in discovering novel microglial reactivity biomarkers and potential microglia-
directed therapeutic approaches to attenuate neuroinflammation. We could establish 
AMWAP and TSPO as suitable microgliosis markers and could show their 
therapeutic potential either as an anti-inflammatory peptide or target structure for 
pharmacotherapy in degenerative diseases of the CNS and retina. 
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